Adıgüzel Aydın, Aypar Ebru, Karagöz Tevfik, Ertuğrul İlker, Aykan Hayrettin Hakan, Alehan Dursun, Güvener Murat, Yılmaz Mustafa, Demircin Metin, Doğan Rıza
Department of Pediatric Cardiology, Hacettepe University, Ankara, Turkey.
Department of Cardiovascular Surgery, Hacettepe University, Ankara, Turkey.
Cardiol Young. 2025 Jan;35(1):38-45. doi: 10.1017/S1047951124025599. Epub 2025 Jan 10.
Ebstein's anomaly represents 40% of congenital tricuspid valve abnormalities. Studies about paediatric Ebstein's anomaly patients are limited.
To evaluate clinical characteristics, treatment (medical/arrhythmia ablation/surgical) results, and outcome of Ebstein's anomaly patients, and to determine factors affecting arrhythmia presence and mortality.
Clinical data, echocardiography, treatment results, and outcomes of patients followed in our centre between 2000 and 2017 were retrospectively evaluated.
A total of 79 patients (61 children, median diagnosis age: 1.5 years [1 day-24 years]) were included. Eight patients (10.1%) were deceased during the study period. Common associated anomalies were atrial septal defect/patent foramen ovale (56.9%), mitral regurgitation (25.3%), pulmonary stenosis/atresia (17.7%), and ventricular septal defect (16.5%). Genetic diseases/congenital anomalies were present in 5/3.8%. Tricuspid regurgitation was present in 75.9%, and severe in 50%. Arrhythmias were detected in 30.4%, and accessory pathway-mediated re-entrant tachycardia was the most common (67%). Wolff-Parkinson-White syndrome was present in 12.7%. Twenty-one ablation procedures (radiofrequency ablation [85.7%]/cryoablation [14.3%]) were performed in 16 patients (median age: 13.3 years [4.9-17]). Acute success/recurrence rates: 87.5/25%. Surgery was performed in 31.6% (median age: 6.5 years [4 days-29 years]), 7.6% were operated during the first month, and 12.6% during the first year. Second surgery was required in 28%. Perioperative mortality rate was 12%, and median mortality age was 25 days (1 day-17 years). Median follow-up period was 5.3 years (1 day-32 years). Older diagnosis age ( = 0.005) and mild-moderate mitral regurgitation ( = 0.036) were associated with arrhythmias. Younger age at diagnosis ( = 0.012), younger age at first surgery ( = 0.004), surgery before age three years ( = 0.037), and presence of pulmonary atresia ( = 0.000014) were associated with mortality. Gender, diagnosis age, congenital anomalies/genetic disorders, tricuspid regurgitation, arrhythmias, and surgery history did not have an independent effect on survival.
In children and young adults presenting with Ebstein's anomaly, younger age at presentation and at surgery, surgery before age three years, pulmonary atresia were associated with death. Ablation procedures can be successfully performed but recurrence rate is still high.
埃布斯坦畸形占先天性三尖瓣异常的40%。关于小儿埃布斯坦畸形患者的研究有限。
评估埃布斯坦畸形患者的临床特征、治疗(药物/心律失常消融/手术)结果及预后,并确定影响心律失常发生和死亡率的因素。
回顾性评估2000年至2017年在本中心随访的患者的临床资料、超声心动图、治疗结果及预后。
共纳入79例患者(61例儿童,中位诊断年龄:1.5岁[1天至24岁])。研究期间8例患者(10.1%)死亡。常见合并畸形有房间隔缺损/卵圆孔未闭(56.9%)、二尖瓣反流(25.3%)、肺动脉狭窄/闭锁(17.7%)及室间隔缺损(16.5%)。5例(3.8%)存在遗传疾病/先天性畸形。三尖瓣反流发生率为75.9%,重度反流占50%。心律失常检出率为30.4%,最常见的是旁路介导的折返性心动过速(67%)。预激综合征发生率为12.7%。16例患者(中位年龄:13.3岁[4.9至17岁])接受了21次消融手术(射频消融[85.7%]/冷冻消融[14.3%])。急性成功率/复发率分别为87.5%/25%。31.6%的患者接受了手术(中位年龄:6.5岁[4天至29岁]),7.6%在出生后第一个月接受手术,12.6%在第一年接受手术。28%的患者需要二次手术。围手术期死亡率为12%,中位死亡年龄为25天(1天至17岁)。中位随访期为5.3年(1天至32年)。诊断年龄较大( = 0.005)及轻中度二尖瓣反流( = 0.036)与心律失常相关。诊断时年龄较小( = 0.012)、首次手术时年龄较小( = 0.004)、3岁前手术( = 0.037)及存在肺动脉闭锁( = 0.000014)与死亡率相关。性别、诊断年龄、先天性畸形/遗传疾病、三尖瓣反流、心律失常及手术史对生存率无独立影响。
在患有埃布斯坦畸形的儿童和年轻成人中,就诊及手术时年龄较小、3岁前手术及肺动脉闭锁与死亡相关。消融手术可成功实施,但复发率仍较高。